Genomictree Inc.
Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2019, the company is a cancer molecular diagnostics firm based on DNA methylation biomarkers. It received MFDS approval in 2018 and launched in 2019 its stool-based colorectal cancer test 'EarlyTect Colorectal Cancer (EarlyTect-C),' which uses the SDC2 gene methylation marker to deliver results within 8 hours. Consolidated 2025 revenue was KRW 3.76 billion, up 59.2% year-on-year, and the company is expanding overseas through its 2019 US subsidiary Promis Diagnostics and a 2020 technology license to Shandong Lukang Haoliyou in China.
Products & technology
- EarlyTect-CStool-based colorectal cancer adjunctive diagnostic test
- EarlyTect bladder/lung cancer diagnosticsBladder and lung cancer adjunctive diagnostic biomarkers
Regulatory approvals
data.go.kr1 Innovative Medical Device designations · 2024 / 16 Korean MFDS device approvals · 2014–2026
- InnovativeGT-BC2-12024-03-19Innovative Medical Device designation
- MFDSIVD reagents for cancer related gene2026-01-08Product approval · Class 3체외 제허 26-19 호
- MFDSSpecimen transport media2024-04-24Product approval · Class 1체외 제신 24-508 호
- MFDSSpecimen transport media2023-01-04Product approval · Class 1체외 제신 23-13 호
- MFDSSpecimen transport media2023-01-04Product approval · Class 1체외 제신 23-12 호
- MFDSIVD reagents for extracting nucleic acids2021-08-26Product approval · Class 1체외 제신 21-1177 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-06-17Product approval · Class 3체외 제허 21-487 호
- MFDSIVD reagents for extracting nucleic acids2021-04-07Product approval · Class 1체외 제신 21-468 호
- MFDSSpecimen transport media2021-03-31Product approval · Class 1체외 제신 21-427 호
- MFDSSpecimen transport media2020-08-20Product approval · Class 1체외 제신 20-1253 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-04-14Product approval · Class 3체외 제허 20-288 호
- MFDSIVD reagents for cancer related gene2019-12-10Product approval · Class 3체외 제허 19-814 호
Show 5 more
- MFDSSpecimen transport media2019-06-03Product approval · Class 1체외 제신 19-724 호
- MFDSIVD reagents for cancer related gene2018-08-28Product approval · Class 3체외 제허 18-593 호
- MFDSIVD reagents for extracting nucleic acids2018-07-02Product approval · Class 1체외 제신 18-792 호
- MFDSIVD reagents for cancer related geneRevoked2018-01-03Product approval · Class 3체외 제허 18-6 호
- MFDSOther reagents, classⅡ, for molecular diagnostics2014-04-14Product approval · Class 2체외 제허 14-854 호
R&D and key agreements
Source: DART corporate disclosureSDC2 유전자 메틸화 마커 · 대장암 · 상용화(얼리텍-C) · Proprietary biomarker; delivers results within 8 hours (vs. ~26 hours for Cologuard)
대장암·방광암 보조진단 제품 미국 FDA 승인 · 대장암, 방광암 · 임상시험 및 승인 절차 진행 예정 · Clinical trials and approval process planned for US FDA approval alongside Korean MFDS approval
Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.
Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-14
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition